Pathway discovered that prevents buildup of Alzheimer’s protein
St. Jude Children’s Research Hospital scientists studying the immune response to brain tumors have identified a pathway that clears a toxic protein that is a hallmark of Alzheimer’s disease
Credit: St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital scientists have discovered a pathway that functions like a car wash to prevent the buildup of a toxic protein associated with Alzheimer’s disease. The report appeared online today in the journal Cell.
The findings in a mouse model of Alzheimer’s offer a possible new approach to treatment of the chronic neurodegenerative disorder, which is the sixth leading cause of death in the U.S. The newly identified pathway also helps regulate inflammation, so the discovery could yield strategies for unleashing the immune response against malignant brain tumors.
Researchers called the pathway LC3-associated endocytosis or LANDO. They found the pathway in microglial cells, the primary immune cells of the brain and central nervous system. However, preliminary evidence suggests LANDO is a fundamental process that functions in cells throughout the body.
Investigators showed that LANDO protected against deposits of neurotoxic β-amyloid protein in mice. Activation of the pathway also guarded against toxic neuroinflammation and neurodegeneration, including memory problems.
“In the context of neurodegenerative diseases such as Alzheimer’s, activating LANDO in microglial cells could prove to be therapeutically beneficial through increased clearance of β-amyloid and mitigation of neuroinflammation,” said corresponding author Douglas Green, Ph.D., chair of the St. Jude Department of Immunology.
While activation of LANDO appears to protect against neurodegenerative disease, first author Bradlee Heckmann, Ph.D., a postdoctoral fellow in Green’s laboratory, said inhibiting the pathway might boost the effectiveness of cancer immunotherapy. “Although in its infancy, preliminary data using a primary brain tumor model suggests that inhibition of LANDO might provide a mechanism to activate inflammation within the tumor microenvironment to generate an anti-tumor response,” Heckmann said.
β-amyloid protein accumulation in neurons is a hallmark of Alzheimer’s. Scientists knew microglial cells take up β-amyloid proteins. Discovery of the LANDO pathway answers questions about what comes next.
Heckmann compared LANDO to the operator of an automatic carwash. In this case, the cars are the receptors on the microglial cells that bind to neurotoxic β-amyloid proteins and bring the protein into the car wash. And, just as cars return to the streets after the dirt is gone, when the β-amyloid is disposed of, the receptor returns to the microglial surface where it can pick up additional β-amyloid.
An automatic car wash depends on hardware to attach the car to a track that moves it through the machine. Similarly, several proteins are required for LANDO functioning. The proteins–Rubicon, Beclin 1, ATG5 and ATG7–are better known for their roles in a related cell pathway used to recycle unneeded and unwanted cell components. These proteins decline with age as their expression decreases.
Follow the data
“You never know where science will lead,” Green said. “This project started because we were studying immune responses against cancer. Brad recognized the findings had relevance to a disease not of children but of older people.
“That’s how science works. When you follow the data, you never know where it will lead.”
The other authors are Brett Teubner, Bart Tummers, Emilio Boada-Romero, Lacie Harris, Mao Yang, Clifford Guy and Stanislav Zakharenko, all of St. Jude.
The research was funded in part by grants (AI40646, CA231620, AI138492, CA231423) from the National Institutes of Health; the Lupus Research Alliance; the John H. Sununu Endowed Fellowship; the Paul Barrett Endowed Fellowship; and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch
Katy Hobgood Ray
Related Journal Article